Cargando…

Primary EBV Infection Induces an Acute Wave of Activated Antigen-Specific Cytotoxic CD4(+) T Cells

CD4(+) T cells are essential for immune protection against viruses, yet their multiple roles remain ill-defined at the single-cell level in humans. Using HLA class II tetramers, we studied the functional properties and clonotypic architecture of EBV-specific CD4(+) T cells in patients with infectiou...

Descripción completa

Detalles Bibliográficos
Autores principales: Meckiff, Benjamin J., Ladell, Kristin, McLaren, James E., Ryan, Gordon B., Leese, Alison M., James, Eddie A., Price, David A., Long, Heather M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AAI 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6697742/
https://www.ncbi.nlm.nih.gov/pubmed/31308093
http://dx.doi.org/10.4049/jimmunol.1900377
Descripción
Sumario:CD4(+) T cells are essential for immune protection against viruses, yet their multiple roles remain ill-defined at the single-cell level in humans. Using HLA class II tetramers, we studied the functional properties and clonotypic architecture of EBV-specific CD4(+) T cells in patients with infectious mononucleosis, a symptomatic manifestation of primary EBV infection, and in long-term healthy carriers of EBV. We found that primary infection elicited oligoclonal expansions of T(H)1-like EBV-specific CD4(+) T cells armed with cytotoxic proteins that responded immediately ex vivo to challenge with EBV-infected B cells. Importantly, these acutely generated cytotoxic CD4(+) T cells were highly activated and transcriptionally distinct from classically described cytotoxic CD4(+) memory T cells that accumulate during other persistent viral infections, including CMV and HIV. In contrast, EBV-specific memory CD4(+) T cells displayed increased cytokine polyfunctionality but lacked cytotoxic activity. These findings suggested an important effector role for acutely generated cytotoxic CD4(+) T cells that could potentially be harnessed to improve the efficacy of vaccines against EBV.